Letter from the Editor


Copyright: This PDF purchase is for a Single user for review or filing purposes only. The PDF is watermarked. If you are interested in a PDF reprint to post on your website or distribute electronically, or hard-copy reprints, please contact Marah Walsh at

SKU: 1830. Category: .

Product Description

The CRO industry is a maturing marketplace. Pharmaceutical companies and the larger biotech companies, as buyers, are more sophisticated. These companies need strategic approaches to their outsourcing needs. And, as a group, CROs have become more sophisticated sellers, offering strategic answers, in addition to tactical approaches, to meet sponsors’ needs. Together, each group must work efficiently to develop partnerships, services, and a business mix in the right framework of pricing and timing. Despite the maturation of the companies serving the pharmaceutical industry, to deliver cost efficient and timely responses to the drug-development process, the industry must continue to become even more efficient at developing drugs in the future. Genomic selection, proteomics, and price controls will hamper the pharmaceutical industry’s ability to maintain the profitability expected by Wall Street and shareholders unless it increases the pipeline and begins…